Abstract:
PROBLEM TO BE SOLVED: To provide new inhibitors for mitotic kinesin, more concretely, for the mitotic kinesin KSP, pharmaceutical compositions comprising the inhibitors, and methods for preparing the inhibitors.SOLUTION: Provided are inhibitors for mitotic kinesin, concretely, for KSP, and a method for producing the inhibitors. Also provided are a pharmaceutical composition comprising the inhibitor, and a method of utilizing the inhibitors and the pharmaceutical composition in the treatment and prevention of various disorders. The compound has usefulness as therapeutic agents for disease treatable by the inhibition of the assembly and/or function of microtubule structures including a mitotic spindle.
Abstract:
PROBLEM TO BE SOLVED: To provide: novel inhibitors of mitotic kinesins, in particular the mitotic kinesin KSP; pharmaceutical compositions containing the inhibitors; and methods for preparing these inhibitors.SOLUTION: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders. Such compounds have utility as therapeutic agents for diseases that can be treated by the inhibition of the assembly and/or function of microtubule structures, including the mitotic spindle.
Abstract:
Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract:
Compounds of Formula I are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract:
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.
Abstract:
Compounds of Formula (I) are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using compounds of Formula (I), and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract:
Pyrazolyl compounds of Formulas Ia and Ib are useful for inhibiting Raf kinase and for treating disorders mediated thereby. Methods of using pyrazolyl compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
Abstract:
This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders.